Agnete Witness Præst Jensen

Agnete Witness Præst Jensen

PhD fellow

Publication year:
  1. 2023
  2. Published

    Phase 2 study of ipilimumab, nivolumab, and tocilizumab combined with stereotactic body radiotherapy in patients with refractory pancreatic cancer (TRIPLE-R)

    Chen, I. M., Donia, M., Chamberlain, C. A., Jensen, Agnete Witness Præst, Draghi, A., Theile, S., Madsen, K., Hasselby, Jane Preuss, Toxværd, A., Høgdall, Estrid Vilma Solyom, Lorentzen, T., Wilken, E. E., Geertsen, P., Svane, Inge Marie, Johansen, Julia Sidenius & Nielsen, D., 2023, In: European Journal of Cancer. 180, p. 125-133 9 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Published

    Proteomics to study cancer immunity and improve treatment

    Franciosa, Giulia, Kverneland, Anders Handrup, Jensen, Agnete Witness Præst, dqp123, dqp123 & Olsen, Jesper Velgaard, 2023, In: Seminars in Immunopathology. 45, 11 p., 241–251.

    Research output: Contribution to journalReviewResearchpeer-review

  4. Published

    TCR-engaging scaffolds selectively expand antigen-specific T-cells with a favorable phenotype for adoptive cell therapy

    Tvingsholm, S. A., Frej, M. S., Rafa, V. M., Hansen, U. K., Ormhøj, M., Tyron, A., Jensen, A. W. P., Kadivar, M., Bentzen, A. K., Munk, K. K., Aasbjerg, G. N., Ternander, J. S. H., Heeke, C., Tamhane, T., Schmess, C., Funt, S. A., Kjeldsen, J. W., Kverneland, A. H., Met, Ö., Draghi, A. & 4 others, Jakobsen, S. N., Donia, M., Svane, Inge Marie & Hadrup, S. R., 2023, In: Journal for ImmunoTherapy of Cancer. 11, 8, 16 p., e006847.

    Research output: Contribution to journalJournal articleResearchpeer-review

ID: 189377138